Recent studies have revealed that nicotinamide N-methyltransferase (NNMT) is able to regulate mitochondrial energy production, a key pathological feature of Parkinson’s disease.
Join Dr Richard Parsons of Kings College London as he discusses this exciting discovery, including the effect of NNMT expression on Complex I activity and energy production, and the cytotrophic effects of NNMT expression on the neurone.
Abcam will process your personal data in strict accordance with its privacy policy which can be found here. This will include sending you updates about Abcam, our products, and resources we think would be of interest to you. You can unsubscribe and manage your marketing preferences by clicking the link at the bottom of every email we send. By filling out this form you consent to Abcam sharing your details with your local, authorized distributor for the purpose of answering your query.
Dr Richard Parsons
Dr Richard Parsons gained his PhD in Biochemistry from The University of Birmingham, UK, studying the metabolism of cysteine in the body. He then undertook a post-doctoral position in the laboratory of David Ramsden, University of Birmingham, where he began his research into the expression of NNMT in PD patients. A subsequent move to the laboratory of Anthony Schapira, UCL, UK found him studying Complex I deficiency in PD.
